Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial

Forrest, A. P. M.; Stewart, Helen; Everington, Dawn; Prescott, R. J.; McArdle, C. S.; Harnett, Adrian; Smith, David C.; George, W D

doi:10.1016/s0140-6736(96)02133-2

Cited by 383 publications

(158 citation statements)

References 15 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…In our study, local relapse occurred in 40 patients (5.7%), which is similar to other studies that have reported a 5-15% rate of local recurrence (Fisher et al, 1995;Clark et al, 1996;Forrest et al, 1996;Renton et al, 1996). However, this result is slightly greater than other Asian series (2.5-4%) (Kim et al, 2005;Yau et al, 2007;.…”

Section: Discussionsupporting

confidence: 90%

HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy

Jia

Jia²,

Feng³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy

Jia

Jia²,

Feng³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…4,10,[12][13][14][15][16][17][18][19] The trials vary with regard to patient selection, the extent of surgery and radiotherapy, and the use of adjuvant systemic therapy. Quadrantectomy was employed in the Milan and Swedish studies, and adjuvant chemotherapy and/or tamoxifen was used in the NSABP, Milan, British, Scottish, and West Midlands trials.…”

Section: Prospective Randomized Trialsmentioning

confidence: 99%

“…13,93 If the breast boost is omitted in these patients, the only available data indicate that the standard whole breast radiation therapy dose is 5,000 cGy at 200 cGy per fraction. 3,4,6,9,14,16,94 …”

Section: Elements In the Technique Of Irradiationmentioning

confidence: 99%

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Morrow

Strom

Bassett

et al. 2002

CA: A Cancer Journal for Clinicians

298

165

View full text Add to dashboard Cite

Multidisciplinary guidelines for management of invasive breast carcinoma from the American College of Radiology, the American College of Surgeons, the College of American Pathology, and the Society of Surgical Oncology have been updated to reflect the continuing advances in the diagnosis and treatment of invasive breast cancer. The guidelines provide a framework for clinical decision‐making for patients with invasive breast carcinoma based on review of relevant literature and include information on patient selection and evaluation, technical aspects of surgical treatment, techniques of irradiation, and follow‐up care.

show abstract

“…[1][2][3][4][5] The results of the recent National Surgical Adjuvant Bowel and Breast Project (NSABP) B-21, showed that radiation therapy was so effective that it would even benefit early breast cancers at minimal risk for IBTR. 6 Therefore, postoperative irradiation was thought to be an important part of standard procedure for BCT.…”

mentioning

confidence: 99%

Ipsilateral breast tumor recurrence (IBTR) after breast‐conserving treatment for early breast cancer

Komoike

Akiyama

Iino

et al. 2005

Cancer

160

103

View full text Add to dashboard Cite

BACKGROUNDThe clinical features of ipsilateral breast tumor recurrence (IBTR) after breast conserving therapy (BCT) for early stage breast cancer were analyzed from long‐term follow‐up of BCT in Japan. The purpose of this study was to clarify risk factors of IBTR and the impact of IBTR on development of distant metastases in this ethnic group.METHODSPatients (N = 1901)with unilateral breast cancer ≤ 3 cm in diameter who underwent BCT at 18 Japanese major breast cancer treatment institutes from 1986 to 1993 were registered in this study. Survival rates, the incidences of IBTR and distant metastases, and annual rates of IBTR and distant metastases after primary operation were calculated by the Kaplan–Meier method. A Cox proportional hazards model was used to estimate the risks of IBTR and distant metastases. A Cox model was also used to estimate the risks of distant metastases after IBTR in the group of IBTR.RESULTSAt a median follow‐up time of 107 months, the 10‐year overall and disease‐free survival rates were 83.9% and 77.8%, respectively. The 10‐year cumulative rates of IBTR were 8.5% in the patients with postoperative irradiation and 17.2% in the patients without irradiation. The 10‐year cumulative distant metastasis rate was 10.9%. On multivariate analysis, young age, positive surgical margin, and omission of radiation therapy were significant predictors of IBTR. In addition, IBTR significantly correlated with subsequent distant metastases (hazard ratio, 3.93; 95% confidence interval, 2.676–5.771; P < 0.0001). Among patients who developed IBTR, initial lymph node metastases and short interval to IBTR were significant risk factors for subsequent distant metastasis.CONCLUSIONSYoung age, positive surgical margin, and omission of radiation therapy seemed to be important factors in relation to local control. The authors' results also indicated that IBTR is significantly associated with subsequent distant metastasis. Patients with positive nodal status at primary operation or with short interval from primary operation to IBTR are at especially high risk of distant metastasis. It remains unclear, however, whether IBTR is an indicator or a cause of subsequent distant metastases. Cancer 2006. © 2005 American Cancer Society.

show abstract

Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial

Cited by 383 publications

References 15 publications

HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy

HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy

Standard for Breast Conservation Therapy in the Management of Invasive Breast Carcinoma

Ipsilateral breast tumor recurrence (IBTR) after breast‐conserving treatment for early breast cancer

Contact Info

Product

Resources

About